- Home
- PTLO vs VSTM Comparison
PTLO vs VSTM Comparison
Compare PTLO & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTLO | VSTM |
|---|---|---|
| Founded | 1963 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.4M | 470.7M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | PTLO | VSTM |
|---|---|---|
| Price | $5.59 | $6.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $8.06 | ★ $16.50 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $732,066,000.00 | $30,914,000.00 |
| Revenue This Year | $9.02 | $282.64 |
| Revenue Next Year | $5.81 | $72.25 |
| P/E Ratio | $20.70 | ★ N/A |
| Revenue Growth | 3.03 | ★ 209.14 |
| 52 Week Low | $4.41 | $4.01 |
| 52 Week High | $13.55 | $11.25 |
Technical Indicators
Market Signals| Indicator | PTLO | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 60.47 |
| Support Level | $5.34 | $6.01 |
| Resistance Level | $6.09 | $6.79 |
| Average True Range (ATR) | 0.22 | 0.39 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 57.86 | 83.24 |
Price Performance
Historical ComparisonAbout PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.